Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$4.93 USD

4.93
4,665,403

+0.22 (4.67%)

Updated May 3, 2024 04:00 PM ET

After-Market: $4.90 -0.03 (-0.61%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NVAX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Novavax, Inc. [NVAX]

Reports for Purchase

Showing records 261 - 280 ( 294 total )

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 261

07/08/2013

Daily Note

Pages: 4

H7N9 Vaccine Construct Enters Clinic, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 262

07/02/2013

Company Report

Pages: 7

Positive Elderly RSV Data Paves Way for RSV/FLU Upper Respiratory Combination Product

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 263

06/14/2013

Company Report

Pages: 7

NVAX Secures Proprietary Vaccine Adjuvant Platform -- MERS-CoV Vaccine Development Update - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 264

05/08/2013

Company Report

Pages: 8

Some Key Questions with RSV Answered in 1Q13

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 265

04/26/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 29

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 266

04/05/2013

Daily Note

Pages: 5

News of a Lethal New Influenza Reported from China Relevant

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 267

04/03/2013

Daily Note

Pages: 5

RSV Vaccine Phase II Results in Women of Childbearing Age Positive , Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 268

03/11/2013

Company Report

Pages: 8

Reports Strong Finish to 2012

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 269

03/04/2013

Company Report

Pages: 5

Q4:12 Update-Top-Line RSV Results Now April, Flu Data

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 270

02/13/2013

Daily Note

Pages: 4

We are terminating research coverage due to the termination or loss of the primary and/or secondary analysts responsible for coverage.

Provider: DAWSON JAMES SECURITIES, INC.

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 271

11/09/2012

Company Report

Pages: 6

Q3:12 Update - Top-Line RSV Results Q1:13 - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 272

11/06/2012

Company Report

Pages: 7

Strong Momentum Going into 2013

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 273

11/06/2012

Company Report

Pages: 8

Strong Momentum Going into 2013

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 274

10/28/2012

Company Report

Pages: 26

Initiation: Doors opening for this vaccine innovator

Provider: BRINSON PATRICK SECURITIES CORPORATION

Analyst: BERNARDINO V

Price: 75.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 275

10/18/2012

Daily Note

Pages: 5

Pandemic Flu Vaccine Data Exceptionally Positive, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 276

09/27/2012

Daily Note

Pages: 5

RSV Data Presentation Shows Potential of Vaccine to Succeed in the Clinic, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 277

09/20/2012

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of September 23

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 278

08/10/2012

Industry Report

Pages: 7

Life Sciences MAC Best Ideas Conference

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 279

08/06/2012

Company Report

Pages: 6

Q2:12 Update - Next Up, Pandemic Flu Data Q4 and RSV Phase II Trial Start - Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 280

07/24/2012

Daily Note

Pages: 5

Novavax Phase II Seasonal Influenza Trial - Primary Endpoints Achieved

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party